Lindy Durrant is a British immunologist who is Professor of Cancer Immunotherapy at the University of Nottingham and Chief Scientific Officer and Chief Executive Officer of the UK AIM listed biotech company Scancell Ltd. Durrant's work focusses on harnessing the immune system to treat cancer and infectious disease. Across her career Durrant has developed a panel of monoclonal antibodies which recognise tumour associated glycans, pioneered novel antibody engineering technology to enhance the avidity of monoclonal antibodies as well as developed a number of different cancer vaccine platforms to target cancers such as melanoma, triple negative breast cancer, head and neck cancer amongst others.
Attributes | Values |
---|---|
rdf:type | |
rdfs:label |
|
rdfs:comment |
|
foaf:name |
|
name |
|
dct:subject | |
Wikipage page ID |
|
Wikipage revision ID |
|
Link from a Wikipage to another Wikipage |
|
sameAs | |
workplaces |
|
dbp:wikiPageUsesTemplate | |
alma mater |
|
has abstract |
|
institution | |
prov:wasDerivedFrom | |
page length (characters) of wiki page |
|
alma mater | |
foaf:isPrimaryTopicOf | |
is foaf:primaryTopic of |